# Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.

> **NCT06787976** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Instituto Mexicano del Seguro Social** · enrollment: 140 (estimated)

## Conditions studied

- HIV
- Insomnia
- Anxiety

## Interventions

- **DRUG:** Dolutegravir (DTG)
- **DRUG:** Darunavir/Cobicistat (FDC)

## Key facts

- **NCT ID:** NCT06787976
- **Lead sponsor:** Instituto Mexicano del Seguro Social
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-19
- **Primary completion:** 2025-12-21
- **Final completion:** 2026-01-25
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06787976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06787976, "Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06787976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*